Tag: Canada
-
Antibodies Prevent Covid-19 Symptoms in Long-Term Care
A clinical trial shows long-term care residents and staff receiving a synthetic antibody treatment have a lower risk of getting symptomatic Covid-19 infections.
-
Tissue Culture: A Novel Propagation Method for Cannabis Industry
One of the more pressing concerns is the development of propagation methods that meet the requirements of mass production.
-
Covid-19 Antibody Developer Raises $483M in IPO
A biotechnology company developing therapeutic antibodies for Covid-19 infections is raising $483 million in its initial public offering of common stock.
-
Industry, Univ Labs Partner on Cannabinoid Pain Drug
A Canadian medical school lab is helping evaluate and develop a pain relief drug made by a company developing therapies from cannabis.
-
Wheat Genome Study IDs Critical Genes, Traits
An international research team identified key features of the complex wheat genome, including genes affecting the grain’s yield, quality, and survival.
-
Lilly, NIH Halt Covid-19 Antibody Therapy Trial
Drug maker Eli Lilly and National Institutes of Health are stopping a clinical trial testing a synthetic antibody to treat hospitalized Covid-19 patients.
-
New Company IDs Drugs Targeting Cancer Cell Networks
A start-up company is using artificial intelligence to discover drugs that address the tumor stroma, a cellular network supporting cancerous tumors.
-
Int’l Lab Network to Assess Covid-19 Vaccines
Six clinical testing laboratories worldwide plan to evaluate vaccines for protecting against Covid-19 infections with a common set of test protocols.
-
Group Advancing Electronic Spinal Cord Injury Therapies
A consortium of academic and industry labs is integrating electronic sensors and neural stimulation therapies into an early treatment protocol for spinal cord injuries.
-
Early Trial Results Show Antibody Treating Covid-19
First results from a clinical trial testing an experimental synthetic antibody, show patients receiving the therapy at a specific dosage, cleared their SARS-CoV-2 viruses within 11 days.